Drugs / Clazakizumab
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07619820 | Jun 2026 → Aug 2027 expected | end stage renal failure | CSL Behring | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03380962 | Feb 2018 → Aug 2025 overdue | chronic renal failure syndrome, chronic transplant rejection, disease related to solid organ transplantation, end stage renal failure | Stanley Jordan, MD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03380377 | Feb 2018 → Apr 2024 | chronic transplant rejection, disease related to solid organ transplantation, glomerular disorder | Stanley Jordan, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01530256 | Mar 2012 → Mar 2013 | acute graft versus host disease | CSL Behring | Terminated | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT05727384 | Aug 2023 → Jan 2026 | — | Anne B. Newman | Completed | No outcome recorded |
| Phase 2 | NCT04494724 | Jul → Dec 2020 overdue | COVID-19 | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04381052 | May 2020 → Apr 2021 | COVID-19 | Columbia University | Terminated | No outcome recorded |
| Phase 2 | NCT04343989 | Mar 2020 → Feb 2021 | COVID-19 | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT04129931 | Dec 2019 → Feb 2025 | asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT01545050 | Jun 2012 → Dec 2013 | Crohn disease | CSL Behring | Terminated | No outcome recorded |
| Phase 2 | NCT02015520 | Jun 2012 → Jun 2013 | rheumatoid arthritis | CSL Behring | Completed | No outcome recorded |
| Phase 2 | NCT01490450 | Dec 2011 → Jun 2013 | psoriatic arthritis | CSL Behring | Completed | No outcome recorded |
| Phase 2 | NCT01403064 | Jul 2011 → Apr 2013 | mucositis | CSL Behring | Terminated | No outcome recorded |
| Phase 2 | NCT01373151 | Jun 2011 → Sep 2012 | rheumatoid arthritis | CSL Behring | Completed | No outcome recorded |
| Phase 2 | NCT00867516 | Oct 2008 → Jun 2009 | rheumatoid arthritis | CSL Behring | Completed | No outcome recorded |
| Phase 2 | NCT00866970 | Sep 2008 → Aug 2009 | non-small cell lung carcinoma | CSL Behring | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05485961 | Oct 2022 → May 2029 expected | end stage renal failure | CSL Behring | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04348500 Comparator | Apr → Sep 2020 | COVID-19 | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03444103 Comparator | Jan 2018 → Jun 2020 | transplant rejection | Medical University of Vienna | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03744910 Comparator | Oct 2019 → Apr 2024 | transplant rejection | CSL Behring | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clazakizumab | “A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)” NCT07619820 ↗12“efficacy of clazakizumab, a monoclonal antibody” PMID 27059799 ↗ Sep 2016 |
| Known as | ALD518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01530256 ↗ |
| Known as | BMS-945429 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01373151 ↗ |
| Known as | CSL300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07619820 ↗ |
| Action | Inhibit | “IL-6 blockade” PMID 27059799 ↗ Sep 2016 |
| Modality | Monoclonal antibody | “a monoclonal antibody with high affinity and specificity for the interleukin-6 (IL-6) cytokine” PMID 27059799 ↗ Sep 2016 |
| Route | Intravenous | “ALD518 160 mg IV on Day 1, Week 8 and Week 16” NCT00866970 ↗ |
| Target | IL6 | “clazakizumab (anti-IL6 monoclonal antibody)” NCT03380377 ↗ |